Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is Nantahala Capital Management LLC’s 10th Largest Position

Nantahala Capital Management LLC raised its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 37.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,665,529 shares of the company’s stock after purchasing an additional 995,586 shares during the period. Amneal Pharmaceuticals accounts for approximately 1.2% of Nantahala Capital Management LLC’s investment portfolio, making the stock its 10th largest holding. Nantahala Capital Management LLC’s holdings in Amneal Pharmaceuticals were worth $29,031,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. MetLife Investment Management LLC increased its holdings in shares of Amneal Pharmaceuticals by 2.5% during the fourth quarter. MetLife Investment Management LLC now owns 94,639 shares of the company’s stock valued at $750,000 after acquiring an additional 2,297 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Amneal Pharmaceuticals by 4.9% in the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock valued at $778,000 after purchasing an additional 4,178 shares during the period. Arizona State Retirement System grew its holdings in shares of Amneal Pharmaceuticals by 13.6% during the fourth quarter. Arizona State Retirement System now owns 40,401 shares of the company’s stock worth $320,000 after buying an additional 4,851 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Amneal Pharmaceuticals by 2.5% during the 4th quarter. Alliancebernstein L.P. now owns 200,246 shares of the company’s stock valued at $1,586,000 after acquiring an additional 4,927 shares during the last quarter. Finally, Globeflex Capital L P grew its holdings in shares of Amneal Pharmaceuticals by 3.8% during the 4th quarter. Globeflex Capital L P now owns 144,439 shares of the company’s stock worth $1,144,000 after purchasing an additional 5,245 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on AMRX shares. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Barclays lifted their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, March 3rd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $10.80.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now owns 1,808,886 shares of the company’s stock, valued at approximately $16,099,085.40. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. This represents a 9.33 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 5,160,000 shares of company stock valued at $43,113,200. Company insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Stock Up 0.8 %

AMRX opened at $7.48 on Monday. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of -11.00 and a beta of 1.06. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $9.48. The company’s 50-day moving average price is $8.06 and its 200 day moving average price is $8.19.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. During the same period last year, the firm posted $0.14 EPS. Research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.